NCT00409110

Brief Summary

This study intends to investigate the relationship between choroidal blood flow and ocular pulse amplitude (OPA).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

December 7, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 8, 2006

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
Last Updated

August 9, 2011

Status Verified

August 1, 2011

Enrollment Period

5.6 years

First QC Date

December 7, 2006

Last Update Submit

August 8, 2011

Conditions

Healthy

Keywords

Ocular Pulse AmplitudeDynamic Contour TonometryPulsatility IndexChoroidal Laser Doppler FlowmetryFinometer

Outcome Measures

Primary Outcomes (1)

  • An association of OPA with the LDF pulsatility index

    30 seconds

Secondary Outcomes (2)

  • An association of OPA with the systemic blood pressure values

    30 seconds

  • An association of OPA with mean intraocular pressure

    30 seconds

Eligibility Criteria

Age45 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

healthy subjects

You may qualify if:

  • Healthy subjects should present no history of ocular diseases, of current topical medication, or of drug or alcohol abuse. Furthermore, a best corrected visual acuity above 20/25 in both eyes, lack of pathological findings upon a slit-lamp examination and dilated direct fundoscopy, and an IOP \< 21 mmHg in both eyes will be required.

You may not qualify if:

  • History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis.
  • History of ocular trauma or intraocular surgery. History of infection or inflammation within the past 3 months.
  • History and clinical evidence for other retinal disease such as age-related degeneration, or diabetic retinopathy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Eye Clinic Basel

Basel, Canton of Basel-City, 4031, Switzerland

Location

Study Officials

  • Selim Orguel, MD

    University Eye Clinic Basel

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 7, 2006

First Posted

December 8, 2006

Study Start

January 1, 2006

Primary Completion

August 1, 2011

Study Completion

August 1, 2011

Last Updated

August 9, 2011

Record last verified: 2011-08

Locations

CH(1)